Despite recommendations in current national guidelines, genetic testing for germline breast cancer susceptibility gene (BRCA) mutations is not discussed with many patients with metastatic breast cancer.

Our podcast emphasizes the importance of early conversations between healthcare providers and patients with metastatic breast cancer about germline BRCA testing and how these results can influence treatment decisions, for example, regarding treatment with poly(ADP-ribose) polymerase inhibitors. As the implications of having a germline BRCA mutation can have an emotional impact on patients, we share insights into how healthcare providers can navigate these discussions with their patients and what the results may mean for a patient’s family members.

Finally, this podcast offers advice to help healthcare providers appropriately tailor conversations about germline BRCA testing with their patients.